Metabolic Reprogramming via Targeting CD38 NADase Augments Adoptive T Cell Therapy.
Where this comes from
- Record sourced from PubMed, PMID 29320709.
- Also identified by DOI 10.1016/j.cmet.2017.12.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
One strategy to improve the potency of adoptive T cell therapy is to augment the function and persistence of anti-tumor T cells. In this issue of Cell Metabolism, Chatterjee et al. (2018) demonstrate that intratumoral CD4+ T cell functions and memory can be improved by targeting a CD38-NAD+-Sirt1-Foxo1 metabolic circuit.
Medical subject headings
- NAD+ Nucleosidase
- Neoplasms